in

Pfizer’s anti-COVID vaccine would call for emerging use in the US today

Internationally, more than 1.3 million people have died from the COVID-19 pandemic

It is estimated that patient zero of the disease was infected on November 17, 2019, more than a year ago

Pfizer Vaccine Trials Involved Patients of All Ages and Ethnic and Demographic Backgrounds

According to ., Pfizer is ready to take the final step necessary to distribute its anti-COVID vaccine in the United States (USA). The North American pharmaceutical company is expected to seek permission from the Food and Drug Administration (FDA) for emergency approval for the formula it developed with BioNTech. It would be the first company in the world that makes a similar request to the institution, and an important step in the battle against the crisis.

The emergency use permit would allow the start of large-scale distribution of the vaccine throughout the country. The application would be submitted today, just days after Pfizer and BioNTech presumed that their formula is 95 percent effective. This, without detecting worrying side effects. Taking into consideration the FDA process for these applications, the vaccine would begin shipping in the US by December.

Sources close to the process told . that members of the institution will discuss the permit between December 8 and 10. Pfizer said that as soon as they get the green light, they will start shipping the vaccine across the country. Now, its supplies are enough to inoculate 25 million people, about a tenth of the population. Given this news, the shares of this pharmaceutical company and BioNTech soared by two and five percent.

The vaccine that could have won the race

It is worth defining what the authorization for emergency use means in the US. According to the FDA itself, it is a resource to allow the distribution and application of treatments, drugs or a vaccine that has not yet been approved. This is allowed only in the context of a crisis and when there is no other alternative with the appropriate permits already on the market. Once the crisis is over, the official authorization has to be granted more properly.

Related Notes

Even if this resource still means that the vaccine may ultimately not fully measure up to the FDA’s strictest standards, this is great news for everyone. According to QIE, the Administration has much stricter measures than other international and local health organizations. In fact, many of its counterparts refer to the decisions of this body for their own drug authorizations.

In this sense, the Pfizer and BioNTech vaccine could be the one that effectively won the great race of this pandemic. The important question is, when could it arrive in Mexico? According to El Universal, it could take a little time for its distribution, due to the special conditions required by the formula. Undersecretary Hugo López-Gatell reported that, until the deep-freezing network is in place, the formula will not be brought. And there is no date for its development.

Other agents who are at the forefront of the process

There are other pharmaceutical companies that are also giving good news about their vaccine. For example, Johnson & Johnson confirmed just a few hours ago how much the dose of its drug will cost. For Mexico, it would be the equivalent of about 200 pesos per dose. While it is more expensive than other rivals have promised, it is also important to mention that it comes down to cost in the US. Other regions of the world could get a lower preferential price.

It is also important to mention AstraZeneca’s advancements. The company said, just shortly after Pfizer revealed the results of its formula’s effectiveness, that its vaccine was also highly effective. Not only that, but it was confirmed in phase two tests that older adults, particularly vulnerable to COVID-19, generate an immune response similar to young people. Something that should help protect them from the pandemic.